Annual Summit on Pharma

Aug 17-18, 2020

|

Melbourne, Australia

Pharma 2020Call for Speakers/Delegates

 About Pharma 2020
 

If we look at the history, innovations don’t come just from giving people incentives, it comes from creating an environment where their ideas can connect. Nobody won’t get ahead by hiding behind old habits and skills; everyone needs to collaborate with the smartest minds in the field. Scientific congresses are still the best way to do that. Pharma 2020 will have its main focus in discussing the latest high impact original clinical research and case reports from all specialities of Medicine and Pharmacy.

 

The Organizing Committee Member of Annual Summit on Pharma to be held in Melbourne, Australia on August 17-18, 2020 will provide a unique platform to unite world’s best professionals in the field of Pharma and to paves a way to gather visionaries through the research talks and presentations and put forward many thought-provoking strategies in this field.

 

With its theme Advancing Healthcare through Pharmaceutical Science” this international conference will provide a unique platform for the global networking with academic institutions, clinical research organizations and with pharmaceutical and biotech industries as they showcase and exhibit their products and services.

Why to attend???

This is your best opportunity to reach the largest assemblage of participants from the Pharma & Pharmaceutical Science community. Live Events -- which include Keynote Sessions, Speaker Sessions, Poster Presentations Video Presentations; provides a unique approach for learning and career building. Attendees will be having an opportunity to build networks with Business Delegates, Academics, and Experts in Pharma, Pharmaceutical Science and Drug discovery across the globe.

Conference Name

Place

Date

Pharma 2020

Melbourne, Australia

Auguast 17-18, 2020

 

Market Analysis

 

Overview

Pharmaceuticals are one of the world's most beneficial ventures. The factors that affect the pharmaceutical market size include disease prevalence, drug affordability, consumer attitudes, government policies and some supply-side factors. Drugs for treating metabolic disorders such as diabetes and diseases of the thyroid and pituitary glands will be the fastest-growing segment of the global pharma market to 2021. This segment will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size.     

Global Analysis

The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.

The largest pharma market globally is for musculoskeletal drugs. These are treatments for diseases such as rheumatoid- and osteoarthritis, osteoporosis, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Major drugs in this segment include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The segment accounted for 14% of the global total in 2017. Cardiovascular, oncology and anti-infective drugs are the second third and fourth-largest markets.

Drugs for treating metabolic disorders such as diabetes and diseases of the thyroid and pituitary glands will be the fastest-growing segment of the global pharma market to 2021. This segment will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size.

Pharmaceutical drugs are subject to a large number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Together with the high R&D costs involved in creating new drug solutions, these can act as barriers to entry for small companies. However, pharmaceutical companies produce both generic and branded drugs. Generics, which are copies of patent-expired drugs, are opportunities for smaller entrants. They are taking an increasing share of the market, particularly in developing economies, where governments are encouraging their production in order to make lower-price treatments more widely available.

In the overall market, top pharmaceutical companies include:

  • Novartis

  • Sanofi

  • Pfizer

  • Hoffman-La Roche

  • Gilead

Together the top ten pharmaceutical companies account for 30% of global sales, making the market moderately fragmented. Within individual segments, however, the share of these pharmaceutical companies varies: Hoffman-La Roche is by some way the leading pharmaceutical company in the large oncology drugs market, but Sanofi leads in the cardiovascular and metabolic disorders segments.

Markets Covered: Musculoskeletal disorder drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorder drugs, central nervous system drugs, genito-urinary drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, ophthalmology drugs, drugs for respiratory diseases.

Pharmaceutical Companies Covered: Novartis AG, Sanofi S.A., F. Hoffman-La Roche Ltd., Pfizer Inc. and Gilead Sciences Inc.

Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.

Countries: USA, China, Japan, Germany, Brazil, France, Italy, UK, Australia, India, Spain, Russia.

Time Series: Five years historic (2013-17) and forecast (2017-21).

Data: Ratios of market size and growth to related markets, population, GDP, Pharmaceutical Drugs Indicators Comparison.

 

Regional Analysis

Australia’s pharmaceutical market is set to rise from just over $22.85 billion in 2016 to $25.2 billion by 2020, registering a compound annual growth rate (CAGR) of 2%, according to research and consulting firm Global Data.

This modest growth will be driven by good market access to pharmaceutical drugs, increasing awareness of the need for the early detection of lifestyle and chronic diseases, the subsidised cost of prescription medicines through the Pharmaceutical Benefits Scheme (PBS) for all eligible patients, and the annual addition of new drugs to the PBS drug list, the report.

According to Global Data, Australia's pharmaceutical market currently represents a knowledge-based, technology-intensive industry, and is positioned to advance Australia’s economic output and social wellbeing.

The industry receives significant financial support from the government through the sale of medicines listed in the PBS and an R&D tax incentive.

Lucy
Rashid Mahmood
General Manager Technical Operations
Surge Laboratories Private Limited

Biography

Rashid Mahmood has a Master Degree in Analytical Chemistry and MS in Total Quality Management. He has 15 years of experience in Pharmaceutical Quality Operations and has attended many international conferences as a keynote speaker.  He has presented various talks in the USA, Canada, UK and UAE on Cleaning Validation, cGMP Guidelines, Quality Risk Management, Role of Mass Spectrometry in Pharmaceuticals and on new Drug Delivery Systems.

Currently, he is working as a General Manager Technical Operations for Surge Lab. (Manufacturer of Microencapsulated APIs, Liquid & Dry Powder Parentrals) which is the best export-oriented organization of Pakistan.

Researches :

  • New Drug Delivery Systems, Quality Risk Management, Cleaning Validation, Microencapsulation, Pharmaceutics & Novel Drug Delivery Systems, Polymer Chemistry, Pharmaceutical cGMP & Hot Melt Extrusion.

Our Collaborations, Sponsors, Media Partners